TacticScaleWhat Tandem Diabetes Care Does & How It Makes Money (TNDM)
Updated October 2026 · reflects Tandem Diabetes Care's latest reported financials
Insulin pump maker for people living with diabetes. It sells insulin pumps, then earns recurring revenue from single-use supplies that users replace regularly, such as insulin cartridges and infusion sets.
How Tandem Diabetes Care makes money
It sells insulin pumps, then earns recurring revenue from single-use supplies that users replace regularly, such as insulin cartridges and infusion sets. Its software tools support the pump system.
What Tandem Diabetes Care does
Tandem Diabetes Care, headquartered in San Diego, designs and sells insulin delivery technology for people with diabetes in the U.S. and internationally. Its flagship t:slim X2 and Tandem Mobi pumps provide automated insulin delivery and integrate with continuous glucose monitors. It works with the University of Virginia Center for Diabetes Technology on research into fully automated closed-loop insulin systems. Besides the pumps, the company sells single-use cartridges and infusion sets that users need on an ongoing basis, which gives it a recurring stream of consumables sales. Its software includes the Tandem Source web platform, the Sugarmate app and the Tandem Device Updater for pump software updates. The company was incorporated in 2006 as Phluid Inc. and took the Tandem name in 2008.
Products & services
- t:slim X2 insulin delivery system
- Tandem Mobi insulin pump
- Insulin cartridges and infusion sets
- Tandem Source data platform
- Sugarmate mobile app
- Tandem Device Updater
What is Tandem Diabetes Care worth?
On an owner-earnings DCF, Tandem Diabetes Care's most-likely value is about $6 versus a recent price near $16 (61% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$2) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 23.7× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Insulet (PODD) · DexCom (DXCM) · Medtronic (MDT) · GlucoTrack (GCTK) · Tonghua Dongbao Pharmaceutical (600867.SS)